The receptor tyrosine kinase EGFR is regulated by complex conformational changes, and this conformational control is disturbed in certain types of cancer. Many ligands are known to bind EGFR in its active conformation, thereby preventing ATP from binding. Only a few ligands are known to stabilize EGFR in its inactive conformation, thus providing novel strategies for perturbing EGFR activity. We report a direct binding assay that enables the identification of novel ligands that bind to and stabilize the inactive conformation of EGFR.
Keywords: cancer; direct binding assay; fluorescence spectroscopy; inhibitors; receptor tyrosine kinase.
© 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.